Skip to content

A single center randomized controlled clinical trial: evaluating the safety and efficacy of aspirin in patients with asymptomatic carotid atherosclerosis / plaque / stenosis in unruptured intracranial aneurysms

A single center randomized controlled clinical trial: evaluating the safety and efficacy of aspirin in patients with asymptomatic carotid atherosclerosis / plaque / stenosis in unruptured intracranial aneurysms

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071437
Enrollment
Unknown
Registered
2023-05-15
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial aneurysms

Interventions

Intervention group:oral aspirin enteric-coated tablet (100mg before breakfast for 6 months) + vitamin B1 tablet (1 tablet, before breakfast, for 6 months)
Control group:oral vitamin B1 tablet (1 tablet, before breakfast, for 6 months)

Sponsors

the First Affiliated Hospital of the Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Consent to enrollment and voluntary signing of the informed consent form; 2. Male or female, aged >= 18 years; 3. Diagnosis of intracranial aneurysm by any one or more of CTA, MRA, DSA; 4. TCD diagnosis of carotid atherosclerosis/plaque/stenosis; 5. The ability to live independently;

Exclusion criteria

Exclusion criteria: 1. Those with contraindications to MRI or MRA; 2. Persons with contraindications to oral aspirin, including but not limited to allergies, bleeding disorders, peptic ulcers, etc; 3. A history of SAH; 4. Have other intracranial vascular disease, including but not limited to arteriovenous malformations (AVMs), arteriovenous fistulas (AVFs), Moyamoya disease, etc; 5. Concomitant use of warfarin or other anticoagulants; 6. PLT < 100*10^9 /L; 7. Concomitant use of steroidal anti-inflammatory drugs, including but not limited to dexamethasone, hydrocortisone, etc. 8. Concomitant use of other non-steroidal anti-inflammatory drugs other than aspirin, including but not limited to diclofenac sodium, ibuprofen, celecoxib, etc; 9. Presence of other organ dysfunctions such as heart, liver and kidney, with an expected survival time of less than 1 year; 10. other patients deemed by the investigator to be unsuitable for inclusion in this study group

Design outcomes

Primary

MeasureTime frame
Changes of CRstalk ;Changes of Ktrans ;The stenosis of carotid diameter >= 50% with TIA;

Secondary

MeasureTime frame
Changes in the number of aneurysms ;Morphological changes of aneurysms;The rupture of aneurysms;The stenosis of carotid diameter >= 70%;

Countries

China

Contacts

Public ContactXia Li

the First Affiliated Hospital of the Air Force Medical University

sjwklixia@sina.com+86 159 9166 6256

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026